ストックスクリーナーアプリを入手
1.03
0.41%
0.00
前日終値:
$1.03
開ける：
$1.04
24時間の取引高:
218.01K
Relative Volume:
0.21
時価総額：
$103.37M
収益：
-
当期純損益:
$-20.31M
株価収益率:
-3.8941
EPS:
-0.2645
ネットキャッシュフロー:
$-21.07M
1週間 パフォーマンス:
-0.56%
1か月 パフォーマンス:
-13.82%
6か月 パフォーマンス:
+147.18%
1年 パフォーマンス:
+8.87%
1日の値動き範囲:
$1.02
$1.05
1週間の範囲:
$0.97
$1.0576
52週間の値動き範囲:
$0.3258
$1.51
Oncolytics Biotech Inc Stock (ONCY) Company Profile
ONCY を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ONCY
Oncolytics Biotech Inc
|
1.03 | 109.33M | 0 | -20.31M | -21.07M | -0.2645 |
|
VRTX
Vertex Pharmaceuticals Inc
|
430.07 | 109.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 82.75B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.71 | 56.78B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
924.63 | 56.52B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.78 | 44.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Oncolytics Biotech Inc Stock (ONCY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-13 | 開始されました | Lake Street | Buy |
| 2022-10-06 | 開始されました | Maxim Group | Buy |
| 2021-02-17 | 開始されました | H.C. Wainwright | Buy |
Oncolytics Biotech Inc (ONCY) 最新ニュース
This Canadian biotech stock is tackling pancreatic Cancer - Cantech Letter
Are Analysts Too Optimistic About Nagreeka Capital Infrastructure Ltds Revenue GrowthGap Up/Gap Down Analysis & Achieve Consistent Profits - earlytimes.in
Oncolytics Biotech (ONCY) Gets a Buy from RBC Capital - The Globe and Mail
Can Oncolytics Biotech Inc. stock sustain free cash flow growthJuly 2025 Sector Moves & Real-Time Volume Surge Alerts - newser.com
Oncolytics Biotech® Provides Update on Special Meeting of Shareholders - BioSpace
Can Oncolytics Biotech Inc. stock attract ESG capital inflowsJuly 2025 Analyst Calls & AI Enhanced Trading Signals - newser.com
Identifying reversal signals in Oncolytics Biotech Inc.Quarterly Profit Report & AI Powered Market Entry Ideas - newser.com
Oncolytics Biotech reschedules special meeting due to government shutdown By Investing.com - Investing.com Nigeria
Oncolytics Biotech Reschedules Shareholder Meeting Amid SEC Delays - TipRanks
Oncolytics Biotech reschedules special meeting due to government shutdown - Investing.com India
Oncolytics Biotech to launch pivotal pancreatic cancer trial in 2026 By Investing.com - Investing.com Australia
FY2025 EPS Estimate for Oncolytics Biotech Lifted by Analyst - MarketBeat
Oncolytics Biotech (TSX:ONC) Growth In Emerging Global Oncology Markets - Kalkine Media
Oncolytics Biotech (TSE:ONC) Advances Clinical Focus in Cancer Therapy - Kalkine Media
Oncolytics Biotech® Aligns with FDA on Pivotal Study Design for Pelareorep in First-Line Pancreatic Cancer - BioSpace
Can Oncolytics Biotech Inc. stock rebound after recent weaknessDollar Strength & Long-Term Growth Portfolio Plans - newser.com
What recovery options are there for Oncolytics Biotech Inc.Quarterly Trade Report & Expert Approved Momentum Ideas - newser.com
Will Oncolytics Biotech Inc. outperform the marketWeekly Stock Summary & Community Consensus Stock Picks - newser.com
Using data tools to time your Oncolytics Biotech Inc. exitTreasury Yields & Low Drawdown Trading Techniques - newser.com
All You Need to Know About Oncolytics Biotech (ONCY) Rating Upgrade to Buy - sharewise.com
Backtesting results for Oncolytics Biotech Inc. trading strategies2025 Technical Patterns & Precise Buy Zone Identification - newser.com
Stocks in play: Oncolytics Biotech Inc - The Globe and Mail
Oncolytics Biotech (ONCY) Advances with FDA-Approved Study Desig - GuruFocus
Oncolytics Biotech Reaches FDA Alignment on Phase 3 Pancreatic Cancer Trial Design - MarketScreener
Oncolytics Biotech to launch pivotal pancreatic cancer trial in 2026 - Investing.com India
Oncolytics, FDA agree on phase 3 trial design for elareorep in pancreatic cancer - Seeking Alpha
Oncolytics Biotech Inc. Aligns with FDA on Pivotal Study Design for Pelareorep in First-Line Pancreatic Cancer - MarketScreener
Oncolytics Biotech rises as US FDA clears path for pancreatic cancer trial - TradingView
Oncolytics (ONCY) and FDA Align on Phase 3 Pelareorep Study Desi - GuruFocus
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B - GlobeNewswire
Oncolytics Biotech rises as U.S. FDA clears path for pancreatic cancer trial - TradingView
Oncolytics Biotech Aligns with FDA for Pivotal Pancreatic Cancer Study - TipRanks
Oncolytics Biotech aligns with FDA on pivotal study design for pelareorep in first-line pancreatic cancer - MarketScreener
Will Oncolytics Biotech Inc. stock keep outperforming rivalsWeekly Investment Summary & Fast Moving Trade Plans - newser.com
Using Ichimoku Cloud for Oncolytics Biotech Inc. technicalsDollar Strength & Growth Oriented Trade Recommendations - newser.com
Heatmap analysis for Oncolytics Biotech Inc. and competitors2025 Risk Factors & Technical Buy Zone Confirmations - newser.com
Analyzing Oncolytics Biotech Inc. with risk reward ratio chartsWeekly Gains Report & Community Verified Trade Alerts - newser.com
Why analysts remain bullish on Oncolytics Biotech Inc. stock2025 Earnings Surprises & Verified Entry Point Signals - newser.com
Oncolytics Biotech (NASDAQ:ONCY) Price Target Raised to $10.00 - MarketBeat
Oncolytics Biotech Forms Advisory Board to Advance Pelareorep in GI Cancers - TipRanks
Oncolytics Biotech stock price target doubled to $10 by H.C. Wainwright - Investing.com South Africa
Oncolytics Biotech (ONCY) Price Target Raised by HC Wainwright | - GuruFocus
The 5-Minute Investor Podcast, Ep. 37: Cancer-fighting stocks | 2025-11-17 | Investing News - Stockhouse
Why Oncolytics Biotech Inc. is moving today2025 Geopolitical Influence & Low Risk High Win Rate Picks - newser.com
Oncolytics Biotech Inc (ONCY) 財務データ
収益
当期純利益
現金流量
EPS
0.69%
1.66%
大文字化:
|
ボリューム (24 時間):